Signature Formulations, LLC – FDA Warning Letter, Sep 15, 2026

Signature Formulations LLC received an FDA warning letter on October 1, 2026, following laboratory tests that confirmed significant contamination in several of its drug products. The FDA’s analysis found that multiple lots contained undeclared active ingredients, posing serious health risks to consumers. These violations fall under the Federal Food, Drug, and Cosmetic Act, as the company failed to follow Current Good Manufacturing Practices (CGMP) by using shared equipment and manufacturing spaces for different types of drugs, leading to cross-contamination. This is a recurring issue for the firm, which has faced previous recalls and regulatory warnings in 2024 and 2025 regarding its inadequate quality systems and lack of management oversight. To address these violations, Signature Formulations has agreed to halt all production and distribution and must voluntarily recall all affected products currently in the market. The FDA requires the company to submit a plan for destroying existing inventory and to hire an expert consultant to redesign their manufacturing processes to ensure safety. A formal response detailing corrective actions is required within fifteen business days.